Cirrus taps Olympic swimmer for endorsement deal
MIAMI BEACH, Fla. One of the United States’ top young Olympic swimmers, Christine Magnuson, will endorse Cirrus Healthcare’s BioEars and ClearEars to the American swim community, Cirrus Healthcare announced.
Known for her prowess as a butterfly swimmer, Magnuson burst onto the scene in 2009 winning an individual NCAA Championship in the 100-yard butterfly and following it up just months later with a silver medal in the 100-meter butterfly and the 4×100-meter medley relay.
“Having a swimmer as successful, both academically and athletically, as Christine representing our brands is very exciting for us at Cirrus,” stated Drew O’Connell, Cirrus CEO. “Her endorsement will help us to highlight the benefits of our innovative products, ClearEars and BioEars, to swimmers throughout the country who are concerned about the health of their ears.”
The deal includes featuring the Olympic double medalist on packaging, in appearances and in print advertising to share the product benefits of Cirrus Healthcare’s swim specific products.
“BioEars allows me to take the precautionary measures necessary to protect my ears when in the water,” Magnuson stated. “I use ClearEars to remove trapped water from my ears following practices or big meets. As a swimmer, you always have to be conscious about ear health.”
Donnenfeld to lead Advanced Vision Research
WOBURN, Mass. Advanced Vision Research on Friday named Neil Donnenfeld the company’s new CEO and director.
Donnenfeld most recently served as SVP global sales and marketing, a position he held since 2005. Donnenfeld, 48, joined AVR in May 1998, shortly after Advanced Vision Research was originally formed as an over-the-counter eye care company to market and distribute TheraTears products.
Donnenfeld succeeds Jeffrey Gilbard, the company’s founder, who passed in August following a bicycle accident.
“I’m honored to have been chosen as the new CEO of Advanced Vision Research where we are dedicated to continuing the path blazed by Dr. Gilbard,” Donnenfeld stated. “We are eager to introduce revolutionary new products that are already in the pipeline, and look forward to the development of new advances in eye care treatment that improve patients’ lives.”
Donnenfeld has been involved in most aspects of building Advanced Vision Research and its brand portfolio, most notably for engineering 12 consecutive years of record sales and profitability for the company across its OTC offerings. Advanced Vision Research was recognized three times by INC magazine as one of the fastest growing privately held companies in America and by Drug Store News as one of the top niche brands for the past four years.
Prior to joining Advanced Vision Research, Donnenfeld was director of marketing at NutraMax Products, a leader in private label health and beauty care. Before that he managed the Bain de Soleil Suncare Brand at Procter & Gamble and worked on other P&G brands including Dramamine, Icy Hot, Clearasil and Oil of Olay.
A resident of Swampscott, Mass., where he resides with his wife Liz and their two daughters, Donnenfeld attended Dartmouth College and received his MBA in Marketing from The Wharton School at the University of Pennsylvania.
Pediatric hospital dispels rumors that Motrin-Robitussin combo is fatal
DALLAS A viral e-mail currently making the rounds between private accounts and public message boards warning of a danger posed by mixing over-the-counter medications Motrin and Robitussin is unfounded, the Children’s Medical Center, a pediatric hospital, reported Friday afternoon.
The e-mail falsely suggests a female patient (usually named Madison or Madeline) died from cardiac arrest after her parents gave her a combination of Motrin and Robitussin. Different versions of the e-mail have been circulating the Internet for more than a year.
In 2009, a Children’s employee received the e-mail from a friend and inadvertently forwarded it from a work account. Because the employee’s professional signature was included at the bottom of the e-mail, the information appeared to come from a reliable source at Children’s Medical Center. This is not the case.
While no child younger than 4 years should be given cough-cold medicines, the Food and Drug Administration has approved combination drugs that mix ibuprofen (the active ingredient in Motrin) and dextromethorphan and/or pseudoephedrine (the active ingredients in Robitussin medications) for older children and adults. There is no evidence to suggest that ibuprofen, dextromethorphan or pseudoephedrine can cause heart attacks in otherwise healthy children or adults when combined.
All medications can have side effects, the hospital noted, and parents of children with underlying medical conditions must always be vigilant about the medications their child is taking. When in doubt, parents should consult their child’s healthcare provider or a pharmacist before mixing over-the-counter medications.